Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics issues 52,000 stock options as employment inducement awards to four new non-executive hires under a Nasdaq-compliant plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dianthus Therapeutics (DNTH) granted equity inducement awards on September 1, 2026 to four newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the independent Compensation Committee as material inducements for employment.
The inducement grants consist of non-qualified stock options to purchase an aggregate of 52,000 shares of common stock, with a 10-year term and an exercise price of $106.62 per share. The options vest 25% on the first anniversary of the vesting commencement date and then in equal monthly installments over the following 36 months. The grants are subject to the company’s Equity Inducement Plan and individual stock option agreements.
Details
News Market Reaction – DNTH
On Sep 3, the first trading day after this news, DNTH closed 1.52% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Grant date
- September 1, 2026
- Inducement awards
- New employees
- 4 employees
- Newly hired, non-executive employees
- Options granted
- 52,000 shares
- Aggregate non-qualified stock options
- Exercise price
- $106.62 per share
- Stock options
- Option term
- 10 years
- Non-qualified stock options
- Initial vesting
- 25%
- Vests on the first anniversary of the vesting commencement date
- Remaining vesting period
- 36 months
- Equal monthly installments after the first anniversary
Historical Context
-
Participation announced for three September investor conferences and related executive meetings
-
Agomab proposed appointments of Dianthus and CRISPR executives to its board
-
Quarterly results combined operating progress with higher expenses and a larger net loss
-
New bifunctional fusion protein showed comparable potency and extended half-life characteristics
-
Equity awards covered six newly hired employees and 87,000 common shares
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 52,000 shares of the Company's common stock with a 10-year term and an exercise price of
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity inducement grants did Dianthus Therapeutics (DNTH) announce on September 2, 2026?
Dianthus Therapeutics announced non-qualified stock option inducement grants to four newly hired, non-executive employees, covering an aggregate of 52,000 shares of common stock. These options were granted on September 1, 2026 and approved by the company’s independent Compensation Committee.
What are the key terms of the Dianthus Therapeutics (DNTH) inducement stock options?
The inducement stock options have a 10-year term and an exercise price of $106.62 per share. Vesting occurs 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next 36 months.
How do the Dianthus Therapeutics (DNTH) inducement grants comply with Nasdaq Listing Rule 5635(c)(4)?
The stock option awards were approved by the company’s independent Compensation Committee and were granted as material inducements to employment for four new non-executive employees, which the company states is in accordance with Nasdaq Listing Rule 5635(c)(4).
How many employees received inducement stock options from Dianthus Therapeutics (DNTH)?
Four newly hired, non-executive employees received the inducement stock option grants from Dianthus Therapeutics. In total, these options give the right to purchase 52,000 shares of the company’s common stock, subject to the stated vesting schedule and plan terms.
Under what plan are the Dianthus Therapeutics (DNTH) inducement stock options granted?
The inducement stock options are granted under the Dianthus Therapeutics Equity Inducement Plan and are subject to its terms and conditions, as well as the provisions of an individual stock option agreement for each recipient.